Abe & Partners

Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox

Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.

• Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing 08-03-2022
• A new drug pricing system reform proposal in Japan 17-08-2021
• Will the EU’s SPC manufacturing waiver weaken European pharma’s IP? 20-05-2020

More abe & partners features